News & Updates

Daily use of topical finasteride 0.25% as monotherapy has resulted in significant increases in hair density and thickness for postmenopausal women with female-pattern hair loss (FPHL) treated in real-world settings, according to a retrospective study.

Treatment with upadacitinib, an oral Janus kinase (JAK)-selective inhibitor, continues to improve skin repigmentation through week 76 in patients with nonsegmental vitiligo (NSV), according to the phase III Viti-Up-1 and -2 studies presented at EADV 2026.

New drug applications approved by US FDA as of 1-15 October 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Respiratory infections in early childhood are a risk factor for atopic dermatitis (AD), and the higher the number of infections, the greater the risk, as shown in a study.

Infantile haemangioma (IH) ulceration may occur in some patients receiving oral propranolol, reports a study, noting independent risk factors for such condition.

A recent study has shown the feasibility of 24-week abrocitinib tapering in well-responding patients with moderate-to-severe atopic dermatitis (AD), reducing treatment burden without compromising efficacy.

Adolescents with moderate-to-severe chronic hand eczema report a considerable improvement in their quality of life following treatment with delgocitinib cream, according to data from the international phase III DELTA TEEN study.